<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33562078</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1650</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22041650</ELocationID><Abstract><AbstractText>LL37 acts as T-cell/B-cell autoantigen in Systemic lupus erythematosus (SLE) and psoriatic disease. Moreover, when bound to "self" nucleic acids, LL37 acts as "danger signal," leading to type I interferon (IFN-I)/pro-inflammatory factors production. T-cell epitopes derived from citrullinated-LL37 act as better antigens than unmodified LL37 epitopes in SLE, at least in selected HLA-backgrounds, included the SLE-associated HLA-DRB1*1501/HLA-DRB5*0101 backgrounds. Remarkably, while "fully-citrullinated" LL37 acts as better T-cell-stimulator, it loses DNA-binding ability and the associated "adjuvant-like" properties. Since LL37 undergoes a further irreversible post-translational modification, carbamylation and antibodies to carbamylated self-proteins other than LL37 are present in SLE, here we addressed the involvement of carbamylated-LL37 in autoimmunity and inflammation in SLE. We detected carbamylated-LL37 in SLE-affected tissues. Most importantly, carbamylated-LL37-specific antibodies and CD4 T-cells circulate in SLE and both correlate with disease activity. In contrast to "fully citrullinated-LL37," "fully carbamylated-LL37" maintains both innate and adaptive immune-cells' stimulatory abilities: in complex with DNA, carbamylated-LL37 stimulates plasmacytoid dendritic cell IFN-&#x3b1; production and B-cell maturation into plasma cells. Thus, we report a further example of how different post-translational modifications of a self-antigen exert complementary effects that sustain autoimmunity and inflammation, respectively. These data also show that T/B-cell responses to carbamylated-LL37 represent novel SLE disease biomarkers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lande</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8398-4567</Identifier><AffiliationInfo><Affiliation>Pharmacological Research and Experimental Therapy Unit, National Centre for Pre-Clinical and Clinical Drug Research and Evaluation, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietraforte</LastName><ForeName>Immacolata</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mennella</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3870-5332</Identifier><AffiliationInfo><Affiliation>Pharmacological Research and Experimental Therapy Unit, National Centre for Pre-Clinical and Clinical Drug Research and Evaluation, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital CHUV, 1011 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palazzo</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pharmacological Research and Experimental Therapy Unit, National Centre for Pre-Clinical and Clinical Drug Research and Evaluation, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Francesca Romana</ForeName><Initials>FR</Initials><Identifier Source="ORCID">0000-0003-1969-2097</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Internistic Sciences, Anesthesiology and Cardiovascular Sciences, University Sapienza, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannakakis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Sapienza, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spadaro</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6610-350X</Identifier><AffiliationInfo><Affiliation>Confocal Microscopy UNIT, Core Facilities, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falchi</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National AIDS Center, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riccieri</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical and Internistic Sciences, Anesthesiology and Cardiovascular Sciences, University Sapienza, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefanantoni</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical and Internistic Sciences, Anesthesiology and Cardiovascular Sciences, University Sapienza, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conrad</LastName><ForeName>Curdin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2547-3440</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital CHUV, 1011 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alessandri</LastName><ForeName>Cristiano</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical and Internistic Sciences, Anesthesiology and Cardiovascular Sciences, University Sapienza, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conti</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical and Internistic Sciences, Anesthesiology and Cardiovascular Sciences, University Sapienza, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frasca</LastName><ForeName>Loredana</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6924-3826</Identifier><AffiliationInfo><Affiliation>Pharmacological Research and Experimental Therapy Unit, National Centre for Pre-Clinical and Clinical Drug Research and Evaluation, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Translational Grant 2019-2021</GrantID><Acronym>NPF</Acronym><Agency>National Psoriasis Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>CO-2018</GrantID><Agency>Ricerca Finalizzata</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023181">Antimicrobial Cationic Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489631">HLA-DRB1*15:01 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059847">HLA-DRB5 Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054804">Cathelicidins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023181" MajorTopicYN="N">Antimicrobial Cationic Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076302" MajorTopicYN="N">Citrullination</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059847" MajorTopicYN="N">HLA-DRB5 Chains</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077279" MajorTopicYN="N">Protein Carbamylation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054804" MajorTopicYN="N">Cathelicidins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LL37</Keyword><Keyword MajorTopicYN="N">post-translational modifications (PTM)</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus (SLE)</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>10</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33562078</ArticleId><ArticleId IdType="pmc">PMC7915858</ArticleId><ArticleId IdType="doi">10.3390/ijms22041650</ArticleId><ArticleId IdType="pii">ijms22041650</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos G.C. Systemic lupus erythematosus. N. Engl. J. Med. 2011;365:2110&#x2013;2121. doi: 10.1056/NEJMra1100359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 2004;75:39&#x2013;48. doi: 10.1189/jlb.0403147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0403147</ArticleId><ArticleId IdType="pubmed">12960280</ArticleId></ArticleIdList></Reference><Reference><Citation>Hancock R.E.W., Haney E.F., Gill E.E. The immunology of host defence peptides: Beyond antimicrobial activity. Nat. Rev. Immunol. 2016;16:321&#x2013;334. doi: 10.1038/nri.2016.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.29</ArticleId><ArticleId IdType="pubmed">27087664</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R., Botti E., Jandus C., Dojcinovic D., Fanelli G., Conrad C., Chamilos G., Feldmeyer L., Marinari B., Chon S., et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat. Commun. 2014;5:5621&#x2013;5635. doi: 10.1038/ncomms6621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6621</ArticleId><ArticleId IdType="pubmed">25470744</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca L., Palazzo R., Chimenti M.S., Alivernini S., Tolusso B., Bui L., Botti E., Giunta A., Bianchi L., Petricca L., et al. Anti-LL37 antibodies are present in Psoriatic Arthritis (PsA) patients: New biomarkers in PsA. Front. Immunol. 2018;9:1936&#x2013;1952. doi: 10.3389/fimmu.2018.01936.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01936</ArticleId><ArticleId IdType="pmc">PMC6154218</ArticleId><ArticleId IdType="pubmed">30279686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R., Palazzo R., Gestermann N., Jandus C., Falchi M., Spadaro F., Riccieri V., James E.A., Butera A., Boirivant M., et al. Native/citrullinated LL37-specific T-cells help autoantbody production in Systemic Lupus Erythematosus. Sci. Rep. 2020;10:5851&#x2013;5864. doi: 10.1038/s41598-020-62480-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62480-3</ArticleId><ArticleId IdType="pmc">PMC7125190</ArticleId><ArticleId IdType="pubmed">32245990</ArticleId></ArticleIdList></Reference><Reference><Citation>Harder J., Schr&#xf6;der J.M. Psoriatic scales: A promising source for the isolation of human skin-derived antimicrobial proteins. J. Leukoc. Biol. 2005;77:476&#x2013;486. doi: 10.1189/jlb.0704409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0704409</ArticleId><ArticleId IdType="pubmed">15629886</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y., Homey B., Cao W., Wang Y., Su B., Nestleet F.O., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564&#x2013;569. doi: 10.1038/nature06116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06116</ArticleId><ArticleId IdType="pubmed">17873860</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N.W., Jin F., Lande R., Curk T., Xian W., Lee C., Frasca L., Frenkel D., Dobnikar J., Gillet M., et al. Liquid-crystalline ordering of antimicrobial peptide&#x2013;DNA complexes controls TLR9 activation. Nat. Mater. 2015;14:696&#x2013;700. doi: 10.1038/nmat4298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmat4298</ArticleId><ArticleId IdType="pubmed">26053762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguly D., Chamilos G., Lande R., Gregorio J., Meller S., Facchinetti V., Homey B., Barrat F.J., Zal T., Gillet M. Self-RNA-antimicrobial peptide complexes activate human dendritic cells though TLR7 and TLR8. J. Exp. Med. 2009;206:1983&#x2013;1994. doi: 10.1084/jem.20090480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20090480</ArticleId><ArticleId IdType="pmc">PMC2737167</ArticleId><ArticleId IdType="pubmed">19703986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., Meller S., Chamilos G., Sebasigari R., Riccieri V., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 2011;3:73ra19&#x2013;73ra38. doi: 10.1126/scitranslmed.3001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001180</ArticleId><ArticleId IdType="pmc">PMC3399524</ArticleId><ArticleId IdType="pubmed">21389263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilsg&#xe5;rd O., Andersson P., Malmsten M., Nordin S.L., Linge H.M., Eliasson M., Soreson E., Erjefalt J.S., Bylund J., Olin A.I., et al. Peptidylarginine deiminases present in the airways during tobacco smoking and inflammation can citrullinate the host defense peptide LL-37, resulting in altered activities. Am. J. Respir. Cell Mol. Biol. 2012;46:240&#x2013;248. doi: 10.1165/rcmb.2010-0500OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2010-0500OC</ArticleId><ArticleId IdType="pubmed">21960546</ArticleId></ArticleIdList></Reference><Reference><Citation>Koro C., Hellvard A., Delaleu N., Binder V., Scavenius C., Bergum B., G&#x142;&#xf3;wczyk I., Roberts H.M., Chapple I.L., Grant M.M., et al. Carbamylated LL-37 as a modulator of the immune response. Innate Immun. 2016;22:218&#x2013;229. doi: 10.1177/1753425916631404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753425916631404</ArticleId><ArticleId IdType="pmc">PMC5143673</ArticleId><ArticleId IdType="pubmed">26878866</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A., Bryzek D., Dobosz E., Scavenius C., Svoboda P., Rapala-Kozik M., Lesner A., Frydrych I., Enghild J., Mydel P., et al. A novel biological role for peptidyl-arginine deiminases: Citrullination ofcathelicidin LL-37 controls the immunostimulatory potential of cell-free DNA. J. Immunol. 2018;200:2327&#x2013;2340. doi: 10.4049/jimmunol.1701391.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1701391</ArticleId><ArticleId IdType="pmc">PMC5860981</ArticleId><ArticleId IdType="pubmed">29475987</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamula M.J., Gee R.J., Elliott J.I., Setta A., Southwood S., Jones P.J., Blier P.R. Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins. J. Biol. Chem. 1999;274:22321&#x2013;22327. doi: 10.1074/jbc.274.32.22321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.32.22321</ArticleId><ArticleId IdType="pubmed">10428801</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle H.A., Mamula M.J. Posttranslational modifications of self-antigens. Ann. N. Y. Acad. Sci. 2005;1050:1&#x2013;9. doi: 10.1196/annals.1313.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1313.001</ArticleId><ArticleId IdType="pubmed">16014515</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Chen B., Mittereder N., Chaerkady R., Strain M., An L.L., Rahaman S., Ma W., Low C.P., Chan D., et al. Spontaneous secretion of the citrullination enzyme PAD2 and cell surface exposure of PAD4 by neutrophils. Front. Immunol. 2017;8:1200&#x2013;1215. doi: 10.3389/fimmu.2017.01200.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01200</ArticleId><ArticleId IdType="pmc">PMC5622307</ArticleId><ArticleId IdType="pubmed">28993780</ArticleId></ArticleIdList></Reference><Reference><Citation>Delporte C., Boudjeltia K.Z., Furtmuller P.G., Maki R.A., Dieu M., Noyon C., Soudi M., Dufour D., Coremans C., Nuyens V., et al. Myeloperoxidase-catalyzed oxidation of cyanide to cyanate: A potential carbamylation route involved in the formation of atherosclerotic plaques? J. Biol. Chem. 2018;293:6374&#x2013;6386. doi: 10.1074/jbc.M117.801076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.801076</ArticleId><ArticleId IdType="pmc">PMC5925816</ArticleId><ArticleId IdType="pubmed">29496995</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. Novel biomarkers containing citrullinated peptides for diagnosis of systemic lupus erythematosus using protein microarrays. Clin. Exp. Rheumatol. 2019;6:929&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">30789148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccarelli F., Perricone P., Colasanti T., Massaro L., Cipriano E., Pendolino M., Natalucci F., Mancini R., Spinelli F.R., Valesini G., et al. Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus. Arthritis Res. Ther. 2018;20:126&#x2013;133. doi: 10.1186/s13075-018-1622-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1622-z</ArticleId><ArticleId IdType="pmc">PMC6001021</ArticleId><ArticleId IdType="pubmed">29898764</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Jia R., Liu Y., Tang S., Li Z. Antibodies against carbamylated vimentin exist in systemic lupus erythematosus and correlate with disease activity. Lupus. 2020;29:239&#x2013;247. doi: 10.1177/0961203319897127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319897127</ArticleId><ArticleId IdType="pubmed">31930936</ArticleId></ArticleIdList></Reference><Reference><Citation>Pecani A., Alessandri C., Spinelli F.R., Priori R., Riccieri V., Di Franco M., Ceccarelli F., Colasanti T., Pendolino M., Mancini R., et al. Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. Arthritis Res. Ther. 2016;18:276. doi: 10.1186/s13075-016-1173-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1173-0</ArticleId><ArticleId IdType="pmc">PMC5124308</ArticleId><ArticleId IdType="pubmed">27887639</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D.D., Iba&#xf1;ez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 2002;29:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., Pascual V. Interferon and granulopoiesis signatures in Systemic Lupus Erythematosus Blood. J. Exp. Med. 2003;197:711&#x2013;723. doi: 10.1084/jem.20021553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021553</ArticleId><ArticleId IdType="pmc">PMC2193846</ArticleId><ArticleId IdType="pubmed">12642603</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissel T., Reijm S., Slot L.M., Cavallari M., Wortel C.M., Vergroesen R.D., Stoeken-Rijsbergen G., Kwekkeboom J.C., Kampstra A., Levarht E., et al. Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications. Ann. Rheum. Dis. 2020;79:472&#x2013;480. doi: 10.1136/annrheumdis-2019-216499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216499</ArticleId><ArticleId IdType="pubmed">32041746</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu Z., Zhang P., Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: A meta-analysis. Int. J. Rheum. Dis. 2015;18:17&#x2013;28. doi: 10.1111/1756-185X.12528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.12528</ArticleId><ArticleId IdType="pubmed">25546242</ArticleId></ArticleIdList></Reference><Reference><Citation>Louthrenoo W., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., Pascual V. The genetic contribution of HLA-DRB5*01:01 to systemic lupus erythematosus in Thailand. Int. J. Immunogenet. 2013;40:126&#x2013;130. doi: 10.1111/j.1744-313X.2012.01145.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1744-313X.2012.01145.x</ArticleId><ArticleId IdType="pubmed">22862923</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H.J., Kim D.H., Lim S.H., Kim W.J., Youn J., Choi Y.S., Choi Y.S. Insights into the role of follicular helper T cells in autoimmunity. Immune Netw. 2014;14:21&#x2013;29. doi: 10.4110/in.2014.14.1.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2014.14.1.21</ArticleId><ArticleId IdType="pmc">PMC3942504</ArticleId><ArticleId IdType="pubmed">24605077</ArticleId></ArticleIdList></Reference><Reference><Citation>Gestermann N., Di Domizio J., Lande R., Demaria O., Frasca L., Feldmeyer L., Di Lucca J., Gilliet M. Netting neutrophils activate autoreactive B cells in Lupus. J. Immunol. 2018;200:3364&#x2013;3371. doi: 10.4049/jimmunol.1700778.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1700778</ArticleId><ArticleId IdType="pubmed">29632142</ArticleId></ArticleIdList></Reference><Reference><Citation>Botto M., Kirschfink M., Macor P., Pickering M.C., W&#xfc;rzner R., Tedesco F. Complement in human diseases: Lessons from complement deficiencies. Mol. Immunol. 2009;46:2774&#x2013;2783. doi: 10.1016/j.molimm.2009.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2009.04.029</ArticleId><ArticleId IdType="pubmed">19481265</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia K.C., Degano M., Pease L.R., Huang M., Peterson P.A., Teyton L., Wilson I.A. Structural Basis of Plasticity in T Cell Receptor Recognition of a Self Peptide-MHC Antigen. Science. 1998;279:1166&#x2013;1172. doi: 10.1126/science.279.5354.1166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.279.5354.1166</ArticleId><ArticleId IdType="pubmed">9469799</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa Y., Kikuchi H., Takahash H. Molecular analysis of TCR and peptide/MHC interaction using P18-I10-derived peptides with a single D-amino acid substitution. Biophys. J. 2007;92:2570&#x2013;2582. doi: 10.1529/biophysj.106.095208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.106.095208</ArticleId><ArticleId IdType="pmc">PMC1864817</ArticleId><ArticleId IdType="pubmed">17208967</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca L., Lande R. Role of post-translational modifications of autoantigens in Systemic lupus erythematosus: LL37 as a model autoantigen. J. Cell. Immunol. 2020;2:308&#x2013;314.</Citation></Reference><Reference><Citation>Borros A. Systemic lupus erythematosus and DNA degradation and elimination defects. Front. Immunol. 2019;10:1697&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6692764</ArticleId><ArticleId IdType="pubmed">31440232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny E.F., Raupache B., Abu Abed U., Brinkmann V., Zychlinsky A. Dnase-1 deficient mice spontaneously develop a systemic lupus erythematosus-like disease. Eur. J. Immunol. 2019;49:590&#x2013;599. doi: 10.1002/eji.201847875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847875</ArticleId><ArticleId IdType="pubmed">30758851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y.W., Tang W., Zuo J.P. Toll-like receptors: Potential targets for lupus treatment. Acta Pharmacol. Sin. 2015;36:1395&#x2013;1407. doi: 10.1038/aps.2015.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2015.91</ArticleId><ArticleId IdType="pmc">PMC4816237</ArticleId><ArticleId IdType="pubmed">26592511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mydel P., Wang Z., Brisslert M., Hellvard A., Dahlberg L.E., Hazen S.L., Bokarewa M. Carbamylation-dependent activation of T cells: A novel mechanism in the pathogenesis of autoimmune arthritis. J. Immunol. 2010;184:6882&#x2013;6890. doi: 10.4049/jimmunol.1000075.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1000075</ArticleId><ArticleId IdType="pmc">PMC2925534</ArticleId><ArticleId IdType="pubmed">20488785</ArticleId></ArticleIdList></Reference><Reference><Citation>Justesen S., Harndahl M., Lamberth K., Nielsen L.L., Buus S. Functional recombinant MHC class II molecules and high-throughput peptide-binding assays. Immunome Res. 2009;5:2&#x2013;21. doi: 10.1186/1745-7580-5-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-7580-5-2</ArticleId><ArticleId IdType="pmc">PMC2690590</ArticleId><ArticleId IdType="pubmed">19416502</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R., Palazzo R., Hammel P., Pietraforte I., Surbeck I., Gilliet M., Chizzolini C., Frasca L. Generation of monoclonal antibodies specific for native LL37 and citrullinated LL37 that discriminate the two LL37 forms in the skin and circulation of cutaneous/systemic lupus erythematosus and rheumatoid arthritis patients. Antibodies. 2020;9:14. doi: 10.3390/antib9020014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib9020014</ArticleId><ArticleId IdType="pmc">PMC7345132</ArticleId><ArticleId IdType="pubmed">32403306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R., Lee E.Y., Palazzo R., Marinari B., Pietraforte I., Santos G.S., Mattenberger Y., Spadaro F., Stefanantoni K., Iannace N., et al. CXCL4 assembles DNA into liquid cristalline complexes to amplify TLR9-mediated interon-a production in systemic sclerosis. Nat. Commun. 2019;10:1731. doi: 10.1038/s41467-019-09683-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09683-z</ArticleId><ArticleId IdType="pmc">PMC6494823</ArticleId><ArticleId IdType="pubmed">31043596</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>